Study of Treatments for Pyoderma GAngrenosum Patients (STOP GAP)
Study of Treatments for Pyoderma GAngrenosum Patients (STOP GAP)
Nottingham.ac.uk
This research project has been designed in order to evaluate the most commonly used treatments for pyoderma gangrenosum.
01-0334274M-25Pyoderma gangrenosum is a very painful skin disease that often affects people with an underlying internal disease (such as inflammatory bowel disease or rheumatoid arthritis). It starts as a reddish purple bump in the skin that develops into a large, deep, spreading ulcer – often very rapidly. People with pyoderma gangrenosum are often misdiagnosed, and spend a long time in hospital waiting for the affected areas to heal.
The STOP GAP study (Study of Treatments for Pyoderma GAngrenosum Patients) is a 5-year randomised controlled trial, funded by the National Institute for Health Research (NIHR). The trial has been set-up to evaluate the efficacy and safety of the two most commonly used systemic treatments for pyoderma gangrenosum. The study aims to test the hypothesis that ciclosporin (4 mg/kg/day) is more effective than prednisolone (0.75 mg/kg/day) for oral therapy of pyoderma gangrenosum.
Recruitment is taking place over a four year period, starting April 2009, in approximately 50 hospitals across the UK and Ireland. Each participant will be enrolled in the study for up to six months (depending on treatment success).
If you would be interesting in hearing more about the trial, please contact the Trial Manager, Eleanor Mitchell: STOPGAP@nottingham.ac.uk or 0115 8230489.
Start date: September 2008
End date: August 2013
Funded by: National Institute for Health Research (www.nihr.ac.uk) under the Programme Grants for Applied Research. The views expressed on this website are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Votes:16
Comments: 0